AbbVie Inc. Press Releases

ABBV 
$56.9
*  
0.61
1.08%
Get ABBV Alerts
*Delayed - data as of Oct. 22, 2014  -  Find a broker to begin trading ABBV now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    ABBV Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
AbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year
10/23/2014 8:00:00 AM - PR Newswire


AbbVie Announces New $5 Billion Stock Repurchase Program and Increases Dividend
10/20/2014 5:31:00 PM - PR Newswire
▲3.66 % Price Change since this news event. The Volume Ratio is 0.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Announcement Of Termination Of Proposed AbbVie And Shire Transaction
10/20/2014 5:12:00 PM - PR Newswire
▲5.98 % Price Change since this news event. The Volume Ratio is 0.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Board Recommends Stockholders Vote Against Shire Transaction
10/15/2014 11:53:00 PM - PR Newswire
▲4.16 % Price Change since this news event. The Volume Ratio is 2.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Announcement Of Notice To Shire Of AbbVie Board Intention To Reconsider Recommendation
10/14/2014 7:44:00 PM - PR Newswire
▲5.57 % Price Change since this news event. The Volume Ratio is 9.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress
10/13/2014 9:20:00 AM - PR Newswire
▲3.83 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and Older
10/6/2014 8:00:00 AM - PR Newswire


AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®
10/1/2014 10:05:00 AM - PR Newswire


AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress
9/27/2014 6:45:00 AM - PR Newswire


AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease
9/25/2014 8:00:00 AM - PR Newswire


AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting
9/22/2014 8:00:00 AM - PR Newswire


AbbVie Declares Quarterly Dividend
9/19/2014 2:08:00 PM - PR Newswire


Hynes Keller & Hernandez, LLC Announces Investigation of World Acceptance Corp., PTC, Inc. and AbbVie Inc.
9/15/2014 7:13:00 AM - PR Newswire


Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
9/12/2014 7:30:00 AM - Business Wire


AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease
9/11/2014 3:00:00 AM - PR Newswire


AbbVie to Present at Morgan Stanley Global Healthcare Conference
9/5/2014 8:00:00 AM - PR Newswire


Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
9/3/2014 4:05:00 PM - PR Newswire


AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies
9/3/2014 1:00:00 PM - PR Newswire


Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
9/3/2014 6:45:00 AM - PR Newswire


AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards
8/18/2014 11:00:00 AM - PR Newswire


INVESTOR ALERT: Investigation of AbbVie Inc. Announced by The Wagner Firm
8/15/2014 3:12:00 PM - Business Wire


AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme
8/4/2014 8:00:00 AM - PR Newswire


AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program
8/1/2014 10:00:00 AM - PR Newswire